Unraveling fibrosis by pharmacological targeting of the G protein-coupled receptor, RXFP1

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1122170

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Peptides, with their high specificity and low toxicity profiles, are highly attractive alternatives to small molecule drugs. H2 relaxin, a peptide hormone, has a strong potential for treating fibrosis. However, the large size of H2 relaxin makes it difficult and expensive to manufacture. Once administered to patients, it is also quickly degraded. We have developed a small anti-fibrotic relaxin peptide, and propose to understand its mechanism of action and improve its therapeutic indices.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $798,618.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Proteins and Peptides

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug design | fibrosis | peptides | pharmacology | relaxin

Related Links